# Phase 2a EBA Trial of AZD5847

> **NCT01516203** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 75 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** AZD5847
- **DRUG:** Ethambutol, isoniazid, pyrazinamide, rifampin

## Key facts

- **NCT ID:** NCT01516203
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-05
- **Primary completion:** 2013-12-12
- **Final completion:** 2013-12-24
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516203, "Phase 2a EBA Trial of AZD5847". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01516203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*